Zsolt Szabo is a Radiologist in Baltimore, Maryland. Dr. Szabo is rated as an Elite provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Febrile Neutropenia, Renal Cell Carcinoma (RCC), Lung Nodules, and WT1-Related Wilms Tumor Syndromes.

John Baddley is an Infectious Disease provider in Baltimore, Maryland. Dr. Baddley is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Cryptococcosis, Shingles, Sepsis, and Febrile Neutropenia.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Dr. Gabrielle Prince is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders. She is viewed regionally as a clinical expert in the care of patients with these disorders and has served as the Principal Investigator for numerous clinical trials studying new treatments for the most challenging clinical cases. Dr. Prince received her undergraduate degree in Biomedical Engineering from Columbia University (New York, NY), earned her M.D. at the State University of New York (Brooklyn, NY), completed her Residency at Columbia University Medical Center-New York Presbyterian (New York, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Prince joined the Johns Hopkins faculty in 2014 at the completion of her training. Her main research interests include drug development for patients with AML, MDS, and MPDs. She has been involved in several clinical trials that helped lead to FDA approval of those new drugs and she remains interested in helping the program maintain a broad-based clinical trials portfolio. Dr. Prince is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Baer is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy. Dr. Baer is currently accepting new patients.

Dr. Nate Permpalung is an Associate Professor of Medicine and serves as the Director of Mycology Research in the Division of Infectious Diseases and Associate Director for Clinical Trials of Transplant Research Center at Johns Hopkins University School of Medicine. In his capacity as a Transplant Infectious Disease physician at Johns Hopkins Hospital, he provides specialized care to immunocompromised patients, including those who have undergone solid organ transplants and those undergoing cancer treatment. His research focuses are respiratory viral infections, invasive fungal infections, fungal-viral interactions, fungal diagnostics, and human pythiosis. Nationally, Dr. Permpalung has served on the panel for the IDSA Aspergillosis Guidelines development and has held editorial positions as Associate Editor for Medical Mycology and as an Editorial Board Member for the Journal of Heart and Lung Transplantation Open. Dr. Permpalung is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Febrile Neutropenia, Parainfluenza, Pneumocystis Jiroveci Pneumonia, and COVID-19.

Dr. Rohini Nadgir is an Assistant Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Her area of clinical expertise is Diagnostic Neuroimaging. Dr. Nadgir earned her B.A. from Columbia University and her M.D. from University of Pennsylvania. She completed her medical internship at Christiana Care Medical Center in Newark, DE and her Diagnostic Radiology residency at Boston University Medical Center. She completed her Neuroradiology fellowship at Johns Hopkins Hospital. Dr. Nadgir joined the Radiology faculty at Johns Hopkins Hospital in 2012. In addition to her clinical work, she has a particular interest in education of residents and fellows in Neuroradiology. She has authored numerous book chapters and contributed to publications focused on Neuroimaging techniques particularly in the head and neck region. Dr. Nadgir is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Cerebellum Agenesis Hydrocephaly, CAPOS Syndrome, Cerebral Arteriovenous Malformation, and Hydrocephalus.

Adam Levin, MD, joined the Johns Hopkins Department of Orthopaedic Surgery as an assistant professor in orthopaedic oncology. Dr. Levin comes to Johns Hopkins after working as an orthopaedic oncologist at the North Shore/LIJ Health System in New York. He completed his residency in orthopaedic surgery at Long Island Jewish Medical Center, and a fellowship in orthopaedic oncology at the Memorial Sloan-Kettering Cancer Center. Dr. Levin offers care and consultations for adults and children with bone and soft tissue tumors of the pelvis and extremities. He has extensive experience in performing limb-sparing and complex extremity reconstruction surgeries. Dr. Levin has a special interest in surgical palliation and biologic reconstruction. Dr. Levin is a member of the American Academy of Orthopaedic Surgeons and the Musculoskeletal Tumor Society. Dr. Levin is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Ollier Disease, Hip Replacement, and Osteotomy.

Dr. Webster is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Webster has expertise in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Dr. Webster received his medical degree from The Stanford University School of Medicine. He completed residency training in internal medicine at Johns Hopkins followed by a fellowship in medical oncology. He completed the Science of Clinical Investigation curriculum at the Johns Hopkins Bloomberg School of Public health. Dr. Webster is a member of the American Society of Hematology, and the American Society of Clinical Oncology. Dr. Webster’s research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of acute leukemias (ALL and AML). He has specific expertise in the use of maintenance therapies following bone marrow transplantation. He has developed novel clinical trials utilizing immunotherapy for the treatment of ALL and the prevention of post-transplant relapse in both ALL and AML. He serves as the Principal Investigator for these trials of post-transplant maintenance strategies, as well as the site PI for multi-center trials that are currently being conducted through the Eastern Co-operative Oncology Group (ECOG)-ACRIN and Experimental Therapeutics Clinical Trials Network (ETCTN). As the leader of the adult ALL program at Johns Hopkins, he has focused on increasing clinical trial enrollments and improving outcomes in adult ALL. Dr. Webster is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Dr. Ghiaur, a member of the Johns Hopkins Kimmel Cancer Center, is a physician-scientist whose primary interest is normal and malignant hematopoiesis, especially the role of the microenvironment in cell extrinsic drug resistance and persistence of minimal residual disease. He has distinguished himself as an outstanding laboratory-based investigator and a superior clinician. His research has translational potential in stem cell therapeutics, as well as acute leukemia and multiple myeloma. Dr. Ghiaur is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Gail Berkenblit is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include infectious disease and internal medicine. Dr. Berkenblit serves as the associate program director for ambulatory education of the Osler Medicine Housestaff Training Program. She received her undergraduate degree from MIT in 1990. She began her medical training in the Health Sciences and Technology joint program between Harvard and MIT. She completed her Ph.D. in the division of cell and developmental biology at Harvard, discovering the role of homeobox genes in uterine development and embryo implantation. She completed medical school and residency training in internal medicine at Johns Hopkins. Her research interests include the design and evaluation of an internet-based curriculum and improving resident training in HIV outpatient care. Dr. Berkenblit serves as chair of the Society of General Internal Medicine’s AIDS Task Force. She was recognized with the David E. Rogers Junior Faculty Education Award by the Society of General Internal Medicine in 2011. Dr. Berkenblit is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Myelitis.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Christian Gocke is a Hematologist in Baltimore, Maryland. Dr. Gocke is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health. Dr. Ali is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Gastrostomy.